Key result
SGLT2 inhibitor prescribing rises ~9 percentage points for outpatients with CKM kidney disease.
Why the study?
Cardiovascular-Kidney-Metabolic-related conditions frequently co-exist and often require multiple medication classes in outpatient care, prompting an evaluation of patient characteristics, comorbidity patterns, and medication prescribing changes during 2024-2025.
Cross-Sectional (n=49,055)
No
This large Vietnamese outpatient study demonstrates a high burden of overlapping cardiovascular-kidney-metabolic (CKM) comorbidities (56-58%) and an increasing trend in the prescription of guideline-recommended SGLT2 inhibitors and DPP-4 inhibitors from 2024 to 2025.
Answers are grounded in this paper and cite their sources.
Modest SGLT2i uptake in Vietnamese CKM outpatients should not change practice; extends CKM framework to Asian cohorts but leaves adoption barriers open.
Background: Cardiovascular - Kidney - Metabolic (CKM)-related conditions frequently co-exist and often require multiple medication classes in outpatient care. Objectives: To describe patient characteristics, comorbidity patterns, and changes in medication prescribing among outpatients during 2024-2025. Methods: A repeated cross-sectional descriptive study was conducted using retrospectively collected electronic health records of patients aged ≥18 years with at least one cardiovascular, kidney, or metabolic diagnosis. In this study, the CKM concept was utilized as a disease categorization framework for analytical purposes; the research did not attempt to establish clinical diagnoses or determine the stage of CKM syndrome according to AHA criteria at the individual patient level. Results: A total of 31,044 patients were identified in 2024 and 31,435 in 2025; 13,424 appeared in both years. The mean age was 57.5 years, and women accounted for 62.4 - 62.9%. Approximately 56 - 58% had conditions involving at least two CKM domains, most commonly metabolic-cardiovascular co-occurrence. Biguanides, renin-angiotensin system agents, and lipid-lowering agents were commonly prescribed. SGLT2 inhibitor prescribing increased from 2.0% to 10.7% in the kidney group and from 0.3% to 2.3% in the metabolic group. Conclusions: The study demonstrates a substantial burden of multimorbidity and changes in outpatient prescribing patterns between the two years. The data do not allow conclusions regarding the causes of these changes or their clinical effectiveness.
No takes yet. Share an insight, caveat, or question.
Trịnh et al. (2026) conducted a cross-sectional in Cardiovascular, kidney, or metabolic (CKM) conditions (n=49,055). Outpatient CKM medication prescribing (2025 vs 2024) vs. 2024 prescribing cohort was evaluated on Patient-level SGLT2 inhibitor prescribing prevalence in the kidney disease group. SGLT2 inhibitor prescribing among outpatients with CKM conditions increased from 2.0% in 2024 to 10.7% in 2025 in the kidney disease group and from 0.3% to 2.3% in the metabolic group.
Synapse has enriched 10 related papers. Consider them for comparative context: